NICE recommends Yervoy for Malignant Melanoma and Zelboraf for Metastatic Melanoma - BMS/Roche

The final draft guidance from NICE (National Institute of Health and Clinical Excellence) recommends Yervoy (ipilimumab) from BMS for the treatment of advanced Malignant Melanoma in people who have received prior chemotherapy, while Zelboraf (vemurafenib) from Roche, is recommended for the treatment of unresectable locally advanced or Metastatic Melanoma in patients who have the BRAF V600 mutation. Both treatments will only be available under separate patient access schemes, however, which will see Roche and BMS cover part of the cost of their respective treatments. The size of the discount involved in both schemes remains confidential.